Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Development and psychometric evaluation of the Spanish version of the lung cancer screening health belief scale

Development and psychometric evaluation of the Spanish version of the lung cancer screening... INTRODUCTIONLung cancer remains the leading cause of cancer death worldwide, largely explained by the majority of lung cancer cases being diagnosed at an advanced stage contributing to the low survival rates (American Cancer Society, 2022). In what is considered a breakthrough in reducing lung cancer‐related mortality, the National Lung Screening Trial in the United States found that lung cancer screening with low‐dose computed tomography (LDCT) of the chest in individuals who have a long‐term smoking history has been shown to decrease relative lung cancer‐related mortality by approximately 20% (National Lung Screening Trial Research Team et al., 2011). In response to these findings, the United States Preventive Services Task Force (USPSTF) issued guidelines in 2013 recommending annual screening with an LDCT of the chest for individuals aged 55–80 years with a 30 pack‐year smoking history who either currently smoke or quit within the past 15 years (USPSTF, 2022a). In 2021, the USPSTF updated the eligibility criteria by decreasing the age of eligibility to 50 years and lowering the pack‐year history to 20 which subsequently increased the number of eligible individuals in the United States (USPSTF, 2022b) Despite the change in eligibility criteria and its intent to be more inclusive, lung cancer screening uptake remains abysmally low, particularly http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Cancer Care Wiley

Development and psychometric evaluation of the Spanish version of the lung cancer screening health belief scale

Download PDF
7 pages

Loading next page...
 
/lp/wiley/development-and-psychometric-evaluation-of-the-spanish-version-of-the-7s1h5a0I7G
Publisher
Wiley
Copyright
© 2022 John Wiley & Sons Ltd
ISSN
0961-5423
eISSN
1365-2354
DOI
10.1111/ecc.13707
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONLung cancer remains the leading cause of cancer death worldwide, largely explained by the majority of lung cancer cases being diagnosed at an advanced stage contributing to the low survival rates (American Cancer Society, 2022). In what is considered a breakthrough in reducing lung cancer‐related mortality, the National Lung Screening Trial in the United States found that lung cancer screening with low‐dose computed tomography (LDCT) of the chest in individuals who have a long‐term smoking history has been shown to decrease relative lung cancer‐related mortality by approximately 20% (National Lung Screening Trial Research Team et al., 2011). In response to these findings, the United States Preventive Services Task Force (USPSTF) issued guidelines in 2013 recommending annual screening with an LDCT of the chest for individuals aged 55–80 years with a 30 pack‐year smoking history who either currently smoke or quit within the past 15 years (USPSTF, 2022a). In 2021, the USPSTF updated the eligibility criteria by decreasing the age of eligibility to 50 years and lowering the pack‐year history to 20 which subsequently increased the number of eligible individuals in the United States (USPSTF, 2022b) Despite the change in eligibility criteria and its intent to be more inclusive, lung cancer screening uptake remains abysmally low, particularly

Journal

European Journal of Cancer Care – Wiley

Published: Nov 1, 2022

Keywords: cancer screening; health belief model; lung; patient reported outcome measures; psychometrics; psycho‐oncology

References

  • Cancer Facts & Figures 2022
  • Using social media for health research: Methodological and ethical considerations for recruitment and intervention delivery
    Arigo, D.; Pagoto, S.; Carter‐Harris, L.; Lillie, S. E.; Nebeker, C.
  • Computer‐tailored decision support tool for lung cancer screening: Community‐based pilot randomized controlled trial
    Carter‐Harris, L.; Comer, R. S.; Slaven, J. E.; Monahan, P. O.; Vode, E.; Hanna, N. H.; Ceppa, D. K. P.; Rawl, S. M.
  • Lung cancer screening participation: Developing a conceptual model to guide research
    Carter‐Harris, L.; Davis, L. L.; Rawl, S. M.
  • Understanding lung cancer screening behaviour using path analysis
    Carter‐Harris, L.; Slaven, J. E.; Monahan, P. O.; Draucker, C. B.; Vode, E.; Rawl, S. M.
  • Development and psychometric evaluation of the lung cancer screening health belief scales
    Carter‐Harris, L.; Slaven, J. E.; Monohan, P.; Rawl, S. M.
  • Patient‐reported outcome (PRO) consortium translation process: Consensus development of updated best practices
    Eremenco, S.; Pease, S.; Mann, S.; Berry, P.
  • Migration and health: A research methods handbook
    Gany, F.; Diamond, L.; Meislin, R.; González, J.
  • Perspective: The case for research justice: Inclusion of patients with limited English proficiency in clinical research
    Glickman, S. W.; Ndubuizu, A.; Weinfurt, K. P.; Hamilton, C. D.; Glickman, L. T.; Schulman, K. A.; Cairns, C. B.
  • IBM SPSS Statistics for Windows, Version 25.0
  • Development and validation of a Mexican version of the champion's health belief model scale for breast cancer screening
    Juárez‐García, D. M.; Valenciano‐Salas, I. A.; Jesús García‐Solís, M.; Téllez, A.
  • Cross‐cultural instrument adaptation and validation of health beliefs about cancer screening: A methodological systematic review [published online ahead of print, 2021 Aug 31]
    Lei, F.; Chen, W. T.; Brecht, M. L.; Zhang, Z. F.; Lee, E.
  • The relationship between demands for lung cancer screening and the constructs of health belief model: A cross‐sectional survey in Hefei, China
    Lu, M. M.; Zhang, T.; Zhao, L. H.; Chen, G. M.; Wei, D. H.; Zhang, J. Q.; Zhang, X. P.; Shen, X. R.; Chai, J.; Wang, D. B.
  • Evaluating the frequency of English language requirements in clinical trial eligibility criteria: A systematic analysis using ClinicalTrials.gov
    Muthukumar, A. V.; Morrell, W.; Bierer, B. E.
  • Reduced lung‐cancer mortality with low dose computed tomographic screening
    Aberle, D. R.; Adams, A. M.; Berg, C. D.; Black, W. C.; Clapp, J. D.; Fagerstrom, R. M.; Gareen, I. F.; Gatsonis, C.; Marcus, P. M.; Sicks, J. D.
  • Potential disparities by sex and race or ethnicity in lung cancer screening eligibility rates
    Pinsky, P. F.; Lau, Y. K.; Doubeni, C. A.
  • ISOQOL recommends minimum standards for patient‐reported outcome measures used in patient‐centered outcomes and comparative effectiveness research
    Reeve, B. B.; Wyrwich, K. W.; Wu, A. W.; Velikova, G.; Terwee, C. B.; Snyder, C. F.; Schwartz, C.; Revicki, D. A.; Moinpour, C. M.; McLeod, L. D.; Lyons, J. C.; Lenderking, W. R.; Hinds, P. S.; Hays, R. D.; Greenhalgh, J.; Gershon, R.; Feeny, D.; Fayers, P. M.; Cella, D.; Butt, Z.
  • Social media recruitment of marginalized, hard‐to‐reach populations: Development of recruitment and monitoring guidelines
    Russomanno, J.; Patterson, J. G.; Jabson Tree, J. M.
  • Awareness and interest in lung cancer screening among current and former smokers: Findings from the ITC United States Survey
    Sharma, A.; Kasza, K.; Hyland, A.; Cummings, K. M.; Bansal‐Travers, M.; Fong, G. T.; O'Connor, R. J.
  • Lower trial participation by culturally and linguistically diverse (CALD) cancer patients is largely due to language barriers
    Smith, A.; Agar, M.; Delaney, G.; Descallar, J.; Dobell‐Brown, K.; Grand, M.; Aung, J.; Patel, P.; Kaadan, N.; Girgis, A.
  • Strategies for overcoming language barriers in research
    Squires, A.; Sadarangani, T.; Jones, S.
  • Language as a barrier to cancer clinical trial accrual: Assessing consenting team knowledge and practices for cancer clinical trial consent among low English fluency patients
    Staples, J. N.; Lester, J.; Li, A.; Walsh, C.; Cass, I.; Karlan, B. Y.; Bresee, C.; Rimel, B. J.
  • The effect of knowledge and health beliefs about colorectal cancer on screening behaviour
    Taş, F.; Kocaöz, S.; Çirpan, R.